Online test nails early Alzheimer’s diagnosis with biomarker precision

Researchers have developed a novel digital cognitive testing platform, using the Oxford Cognitive Testing Portal, that correlates with serological biomarkers to accurately measure cognitive impairment in Alzheimer’s patients. The study highlights the platform’s effectiveness in capturing subtle signs of impairment, potentially revolutionizing early diagnosis and tracking of Alzheimer’s disease.

Formycon and Fresenius Kabi announce European Medicines Agency Submission Acceptance of the Marketing Authorization Application for FYB202, an Ustekinumab Biosimilar Candidate – Biotech Investments

EQS-News: Formycon AG / Key word(s): Regulatory Admission/Miscellaneous Formycon and Fresenius Kabi announce European Medicines Agency Submission Acceptance of the Marketing Authorization Application for FYB202,

September 30, 2023

Opinion | Was the FDA Panel Right to Recommend Against MDMA Approval?

Das is an addiction psychiatrist. Untreated mental health concerns remain devastating for our nation, and there is an ongoing need for expanded options and access.

June 12, 2024

First Opinion readers on Hatch-Waxman, new-patient visit times, mpox, and more

First Opinion is STAT’s platform for interesting, illuminating, and provocative articles about the life sciences writ large, written by biotech insiders, health care workers, researchers,

October 5, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.